New research could help physicians tailor asthma therapy in children
From the February 2005 Journal of Allergy & Clinical Immunology
Researchers have identified specific asthma characteristics in children that could help determine the type of asthma treatment they will best respond to. These findings were published in the February 2005 Journal of Allergy & Clinical Immunology (JACI). The JACI is the peer-reviewed, scientific journal of the American Academy of Allergy, Asthma and Immunology (AAAAI). "Parents of children with asthma often ask: Is there a good way to determine what medication will work best in my child?" said Stanley J. Szefler, MD, FAAAAI. "These findings begin to address this question by taking a step toward enabling clinicians to better individualize asthma therapy."
Dr. Szefler and colleagues from the National Heart, Lung, and Blood Institutes (NHLBIs) Childhood Asthma Research and Education (CARE) Network found specific differences in responses to the inhaled corticosteroid, fluticasone, and the leukotriene receptor antagonist, montelukast, in children with mild-to-moderate persistentasthma.
Inhaled corticosteroids are anti-inflammatory medications that go directly into the lungs, reducing inflammation in the airways. Leukotriene receptor antagonists treat asthma differently by blocking substances in the lungs called leukotrienes, which cause narrowing and swelling of the airways. While both medications are considered effective daily treatments for long-term care and prevention of exacerbations in patients of all ages with persistent asthma (those who have symptoms at least two days a week or two nights a month), the National Asthma Education and Prevention Program asthma treatment guidelines list inhaled corticosteroids as the preferred treatment, with leukotriene modifiers one of several alternative therapies.
"There is increasing evidence that children respond differently to the various treatment options for asthma," noted James Kiley, PhD, director of the NHLBI Division of Lung Diseases. "If we can pinpoint in advance which children will do better with a certain type of therapy, we can improve their lives more quickly and save them the risk of trying medications that are less effective for them. This study adds important information for identifying which children are more likely to respond well to inhaled corticosteroids."
Researchers administered fluticasone and montelukast separately for 8 weeks to 126 children (ages 6 to 17 years) with mild-to-moderate persistent asthma. During the course of the study, researchers evaluated the childrens lung function in response to each therapy to determine which medication produced the most favorable response.
The researchers reported on the percentage of children who improved lung function by 7.5% or greater based on a standard test. They found:
- 17% of the children reached the goal when taking both medications
- 23% of the children reached the goal when taking only the inhaled corticosteroid
- 5% of the children reached the goal when taking only the leukotriene receptor antagonist
- 55% of the children reached the goal when taking neither medication
Researchers noted that children whose asthma improved with inhaled corticosteroids had low pulmonary function and elevated markers of allergic inflammation at baseline. On the other hand, the children whose asthma was improved only by the leukotriene receptor antagonist were younger in age and had a shorter duration of the disease.
Based on these findings, researchers recommend that children with mild-to-moderate persistent asthma who have low lung function and/or elevated signs of allergic inflammation be treated daily with inhaled corticosteroids. Their findings also suggest that, in those children who have no elevated signs of allergic inflammation, a therapeutic trial of either medication can be conducted to determine which works best.
John Gardner | EurekAlert!
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.
The results will be published on March 22 in the journal „Astronomy & Astrophysics“.
Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...
Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.
Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...
Layered 2D material improves efficiency for solar cells and LEDs
In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...